Abbot receives CE Mark for Tecnis Symfony extended range of vision IOL

Article

Abbott recently announced it has received CE Marking (Conformité Européenne) in Europe for the Tecnis Symfony extended range of vision intraocular lens (IOL) for the treatment of cataract patients who may also have presbyopia.

Abbott Park, IL-Abbott recently announced it has received CE Marking (Conformité Européenne) in Europe for the Tecnis Symfony extended range of vision intraocular lens (IOL) for the treatment of cataract patients who may also have presbyopia.

According to Abbott, the Tecnics Symfony IOL is intended to provide a continuous range of vision, including far, intermediate, and near distances with reduced incidence of halo and glare comparable to a monofocal lens. The Tecnis Symfony IOL is not approved for use in the United States. 

Abbott began a 150-patient study in Europe to evaluate patients' quality of vision at far, intermediate, and near distances after being implanted in both eyes with the Tecnis Symfony IOL. The study will also assess both patient and surgeon satisfaction. Preliminary study results are anticipated later this year. The company is also conducting a post-market observational study with approximately 400 patients across Europe, including the United Kingdom, France, Germany, and Spain, with results expected at the end of 2014.

Recent Videos
Jennifer Li, MD, details a talk she gave alongside Melissa Barnett, OD, FAAO, FSLS, FBCLA, at CRU 2025 in Napa, California.
Deb Ristvedt, DO, details a handful of presentations on glaucoma she gave during CRU 2025 in Napa, California.
Cecelia Koetting, OD, FAAO, DipABO, weighs in on patient assessments, staining pattern insights, and diagnostic tips for patients who may have dry eye disease.
Melissa Barnett, OD, FAAO, FSLS, FBCLA, discusses keratoconus management, diagnosis, and other key insights at CRU 2025.
Cecelia Koetting, OD, FAAO, DipABO, details a talk she gave among optometrists and ophthalmologists at CRU 2025.
Alongside Rachelle Lin, OD, MS, FAAO; Nguyễn, MD, MSc, detailed what treatments are currently available for retinal vascular diseases, including neovascular age-related macular degeneration and diabetic retinopathy.
Dr Paul Karpecki discusses atropine formulation from Sydnexis following NDA acceptance by FDA
Ali Tafreshi sits down with Optometry Times to discuss Topcon's "Healthcare from the Eye" initiative.
Nora Lee Cothran, OD, FAAO, details a real-world study that found IOP-lowering benefits when switching patients with glaucoma to latanoprostene bunod treatment.
OptiLIFT in action: Dr. Julie McLaughlin's experience with the new device
© 2025 MJH Life Sciences

All rights reserved.